Navigation Links
Arena Pharmaceuticals Announces Second Quarter 2009 Financial Results and Recent Developments
Date:8/3/2009

erweight patients with type 2 diabetes. Results from BLOOM-DM will be submitted as a supplement to the lorcaserin NDA filing.
  • Announced a late-breaking poster presentation of positive results from BLOOM (Behavioral modification and Lorcaserin for Overweight and Obesity Management), the first of two pivotal trials evaluating the safety and efficacy of lorcaserin for weight management, at the 69th Scientific Sessions of the American Diabetes Association. Lorcaserin patients achieved highly significant categorical and absolute weight loss in Year 1, and continued treatment with lorcaserin in Year 2 helped significantly more patients maintain their weight loss as compared to those on placebo. 66.4% of lorcaserin patients who completed one year of treatment according to the trial's protocol lost at least 5% of their weight and the average weight loss in this responder population was 26 pounds. Treatment with lorcaserin also resulted in highly significant improvements as compared to placebo in multiple secondary endpoints associated with cardiovascular risk. Lorcaserin was very well tolerated, did not result in increased risk of depression and was not associated with development of cardiac valvular insufficiency.
  • Ortho-McNeil-Janssen completed a Phase 1 clinical trial evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of a single ascending dose of APD597 in healthy volunteers. Ortho-McNeil-Janssen has initiated another clinical trial evaluating multiple ascending doses of APD597.
  • Completed a public offering of 12.5 million shares of common stock, resulting in net proceeds to Arena of approximately $49.7 million.
  • Received net proceeds of $95.6 million from a $100.0 million secured loan provided by Deerfield Management. The outstanding principal accrues interest until maturity in June 2013 at a rate of 7.75% per annum. In connection with the loan, Arena issued Deerfield warrants for 28 million
    '/>"/>

  • SOURCE Arena Pharmaceuticals, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10

    Related medicine news :

    1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
    2. Arena Pharmaceuticals Announces Public Offering of Common Stock
    3. Arena Pharmaceuticals to Present at the BIOCOM Investor Conference
    4. Arena Pharmaceuticals Announces Pricing of Public Offering of Common Stock
    5. Arena Pharmaceuticals to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
    6. Arena Pharmaceuticals Lorcaserin for Obesity Passes Major Safety Milestone
    7. Arena Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
    8. Arena Pharmaceuticals to Report First Quarter 2008 Financial Results and to Host Conference Call and Webcast on Wednesday, May 7, 2008
    9. Field Poll: California Nurses Association Most Favorably Viewed Group in Healthcare Arena
    10. Childrens Miracle Network and Arena Football League Partner for First Nationwide Celebration Event
    11. Arena Pharmaceuticals Announces Third Quarter 2008 Financial Results
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:6/3/2015)... The National Resident Matching Program ... Savoia, M.D., Dean of Medical Education at the University of ... on July 1. , “It is an honor ... Matching Program,” said Dr. Savoia. “NRMP’s goal is to ... students with training programs, and I welcome the opportunity to ...
    (Date:6/3/2015)... California (PRWEB) June 03, 2015 ... biopharmaceuticals or biologics has revolutionized disease treatment on account ... cancer and autoimmune diseases, such as rheumatoid arthritis. The ... the use of traditional small molecule drugs to biopharmaceuticals ... monoclonal antibodies (mAbs), cell and gene therapies, and recombinant ...
    (Date:6/3/2015)... On June 22, 2015, Medicare will begin ... (pharmacogenetic) testing that it has reimbursed since 2009. , ... million of the 49 million Medicare beneficiaries in the U.S. ... drug events.(1) Sadly, if it became a standard of care, ... use of an individual’s genetic information to tailor treatment, is ...
    (Date:6/3/2015)... On the heels of a report predicting ... 2020 ( click here to review news coverage about ... Baltimore has the talent to become a world-leading center ... and other biological data are collected and analyzed to help ... all the elements of a perfect storm for bioinformatics leadership,” ...
    (Date:6/3/2015)... 2015 Vancouver personal injury lawyers at ... will now handle personal injury claims resulting due to ... rise, more and more people turn towards mass transportation ... needless suffering, serious injury and also deaths. , ... bus accident in BC you may have an ICBC ...
    Breaking Medicine News(10 mins):Health News:NRMP Board of Directors Elects New Leadership and Members at its May 2015 Meeting 2Health News:NRMP Board of Directors Elects New Leadership and Members at its May 2015 Meeting 3Health News:NRMP Board of Directors Elects New Leadership and Members at its May 2015 Meeting 4Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:Superior Efficacy of Biopharmaceuticals Against Chronic Diseases Drives the Global Biopharmaceuticals Market, According to a New Report by Global Industry Analysts, Inc. 4Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 2Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 3Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 4Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 5Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 6Health News:Medicare Limiting Coverage Benefit for Drug Sensitivity Testing on June 22, 2015 7Health News:Baltimore Poised to Become a World-Leading Hub of Multi-Billion Dollar Bioinformatics Industry 2Health News:Baltimore Poised to Become a World-Leading Hub of Multi-Billion Dollar Bioinformatics Industry 3Health News:Jiwa Law Corporation Now Handles Personal Injury Claims Involving Bus Accidents 2
    ... ... own the issue of “medication adherence.” , ... Alexandria, VA (Vocus) April 10, 2010 -- An article in ... fueling the National Association of Chain Drug Stores’ (NACDS) message that pharmacy’s role in ...
    ... Key Topics in Surgical Research and Methodology represents a ... an academic career. Four key elements are covered: ... Research as well as Recent Developments and Future Prospects ... "The aim of this book is to equip surgeons ...
    ... the United States has experienced a conflict with a ... care, researchers from the University of Chicago report in ... of General Internal Medicine . Younger and less ... than their older or more religious peers. Most primary ...
    ... say , FRIDAY, April 9 (HealthDay News) -- Doctors ... detect chronic liver disease in children, new research finds. ... (ALT) activity, is designed to detect liver disease or ... assessment of the test levels considered to be signs ...
    ... begin exercise program early recover faster, reduce sedative use, research ... patients in the intensive care unit may reduce their use ... exercise, a new study has found. , The amount of ... patients to exercise, which reduced the amount of muscle weakness ...
    ... ... was named a 2009 “Purveyor of the Year” by Outback Steakhouse Inc. (OSI) for ... custom, strategic learning solutions to help cascade strategies throughout its workforce to increase satisfaction ... ...
    Cached Medicine News:Health News:New England Journal of Medicine Article Trumpets “Priority” Status of Helping Patients Take Medications Correctly 2Health News:New England Journal of Medicine Article Trumpets “Priority” Status of Helping Patients Take Medications Correctly 3Health News:Primary care physicians nationwide face clinical ethical conflicts with religious hospitals 2Health News:Liver Disease May Go Undetected in Children 2Health News:Mild Exercise Good for the Critically Ill 2Health News:Root Learning Named “Purveyor of the Year” For Strategic Partnership with Outback Steakhouse 2
    (Date:6/3/2015)... 2015  Giving people with low vision hope – ... International Academy of Low Vision Specialists (IALVS), ... at the forefront of low vision care. The academy ... and latest treatment options available to patients who present ... traditional means. Recently, doctors in six new states and ...
    (Date:6/3/2015)... Va. , June 3, 2015  PARI Respiratory Equipment ... Pak ® .  Kitabis Pak, approved by the FDA on ... solution with a PARI LC PLUS ® Nebulizer for ... all the hard work we put into this unique product ... that is easy for patients to use, we also wanted ...
    (Date:6/3/2015)...  OncoSec Medical Inc. ("OncoSec") (NASDAQ: ONCS ... today announced that it has entered into definitive ... approximately $13.6 million of securities in a registered ... such investors an aggregate of 2,469,091 shares of ... per share. The gross proceeds ...
    Breaking Medicine Technology:International Academy of Low Vision Specialists Announces Training of Doctors in Six New States and Canada 2International Academy of Low Vision Specialists Announces Training of Doctors in Six New States and Canada 3International Academy of Low Vision Specialists Announces Training of Doctors in Six New States and Canada 4Kitabis Pak Wins American Package Design Award 2OncoSec Medical Announces $13.6 Million Registered Direct Offering 2OncoSec Medical Announces $13.6 Million Registered Direct Offering 3
    ... 20-year history, the VOYAGER RX Dilatation Catheter ... outcomes. It combines a new low profile, ... shaft,more flexible markers, and short taper balloon ... tortuous anatomy with even greater confidence, opening ...
    ... Utilizing technology developed over Guidants 20-year history, ... new foundation for successful treatment outcomes. It ... design with a lower profile shaft,more flexible ... you can cross tight and tortuous anatomy ...
    ... Utilizing technology developed over Guidants 20-year ... the new foundation for successful treatment outcomes. ... tip design with a lower profile shaft,more ... Now you can cross tight and tortuous ...
    The assay is an immunometric ('sandwich') EIA for the quantitative measurement of AFP in human serum or plasma....
    Medicine Products: